https://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood. https://medicalxpress.com/news/2026-08-class-therapy-undruggable-protein-hard.html Sat, 22 Aug 2026 10:35:57 EDT news706613730 A two-headed molecule designed by Stanford Medicine researchers hijacks one of the most common protein drivers of B-cell lymphoma, flipping it from its role as a promoter of cell growth into an arbiter of cell death. In mice, a short course of twice-daily treatment eliminated aggressive lymphoma tumors within 11 days. https://medicalxpress.com/news/2026-08-molecular-redirects-cancer-protein-cell.html Thu, 20 Aug 2026 12:00:07 EDT news706439536 Vaccines protect most people from serious illness, but the strength of that protection can vary considerably from one person to another. A new study led by Arizona State University helps us understand why. https://medicalxpress.com/news/2026-08-immune-responses-vaccines-vary-person.html Thu, 20 Aug 2026 11:00:10 EDT news706347841 Adults who have survived Hodgkin lymphoma (HL) for at least five years face significantly elevated long-term health risks, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. https://medicalxpress.com/news/2026-08-hodgkin-lymphoma-survivors-death-average.html Wed, 19 Aug 2026 20:00:04 EDT news706356075 Of more than 500 occupations in the United States, flight attendants and pilots have the highest and second-highest proportions of radiation-related cancer deaths, a new study has found. https://medicalxpress.com/news/2026-08-flight-greater-cancer-death.html Mon, 17 Aug 2026 11:00:08 EDT news706181341 A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow of patients with multiple myeloma and acute myeloid leukemia. The work has been published in Cancer Cell. https://medicalxpress.com/news/2026-08-analysis-bone-marrow-cancer-cells.html Mon, 10 Aug 2026 16:00:06 EDT news705587282 Experts at City of Hope, one of the nation's largest and most advanced cancer research and treatment organizations, are shining a spotlight on the risk of skin cancer faced by hematopoietic cell transplant (HCT) survivors, as well as the need for early detection. New City of Hope research published in Journal of the National Comprehensive Cancer Network shows how a cost-effective, scalable education program targeting survivors and their doctors can significantly improve screening. https://medicalxpress.com/news/2026-08-outreach-bone-marrow-transplant-survivors.html Thu, 06 Aug 2026 17:00:05 EDT news705231632 An international research team led by the Medical University of Vienna reports on a new treatment strategy that has made kidney transplantation possible for a patient with no realistic chance of receiving a suitable donor organ. https://medicalxpress.com/news/2026-07-cancer-drug-enables-kidney-transplant.html Thu, 30 Jul 2026 16:20:01 EDT news704645881 In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, and produced a median duration of response of 11.2 months before the cancer progressed. https://medicalxpress.com/news/2026-07-therapeutic-options-multiple-myeloma.html Wed, 22 Jul 2026 16:20:03 EDT news703946283 When the BBC presenter Lauren Laverne revealed she has smoldering myeloma, the diagnosis sounded more alarming than it is. Her situation is more subtle and nuanced than the word "myeloma" suggests. https://medicalxpress.com/news/2026-07-smoldering-myeloma-lauren-laverne-diagnosis.html Tue, 21 Jul 2026 12:00:04 EDT news703846383 Australian researchers have found a new biomarker for multiple myeloma that could help doctors rapidly identify patients at greatest risk of poor outcomes, enabling more personalized and effective treatments. Multiple myeloma is an incurable cancer of plasma cells in the bone marrow and is the second most common blood cancer worldwide, with more than 188,000 new cases diagnosed each year. https://medicalxpress.com/news/2026-07-blood-cancer-marker-patients-high.html Tue, 21 Jul 2026 11:00:05 EDT news703844942 Researchers have found that, with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use different criteria to identify patients with poor chances of survival. The study was published online in Cancer. https://medicalxpress.com/news/2026-07-clinical-blood-cancer.html Mon, 20 Jul 2026 03:00:01 EDT news703491497 For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3 clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), published today in the New England Journal of Medicine, found more toxicity with no survival benefit from continuing treatment until disease progression compared with stopping after 2 years. https://medicalxpress.com/news/2026-07-myeloma-maintenance-years-survival-loss.html Thu, 16 Jul 2026 07:00:07 EDT news703403046 New research has uncovered why one of the most widely used treatments for multiple myeloma can cause debilitating nerve and gastrointestinal side effects, marking a significant step toward preventing them. https://medicalxpress.com/news/2026-07-gut-microbiome-emerges-key-clue.html Wed, 15 Jul 2026 11:00:04 EDT news703325972 Researchers at The University of Texas MD Anderson Cancer Center have created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study provided insights that may explain why patients with similar diagnoses often have different disease progression, treatment responses and outcomes. https://medicalxpress.com/news/2026-07-immune-ecotypes-multiple-myeloma-outcomes.html Wed, 15 Jul 2026 07:40:03 EDT news703318943 New research from VCU Massey Comprehensive Cancer Center provides evidence for a combination treatment strategy that uses cells' waste-removal functions to target multiple myeloma. The findings, published recently in Cell Death & Disease, show how an experimental targeted protein degrader developed at the cancer center enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs in preclinical models while showing limited toxicity in cardiac models. https://medicalxpress.com/news/2026-07-combination-treatment-harnesses-cellular-recycling.html Tue, 14 Jul 2026 07:00:01 EDT news703229629 An interdisciplinary team at Jena University Hospital achieved a surprisingly rapid and significant improvement in two patients with an autoimmune peripheral nervous system disorder. The team administered teclistamab, a drug originally developed for multiple myeloma, and reported in detail in Nature Communications. https://medicalxpress.com/news/2026-07-repurposed-cancer-drug-rapidly-eased.html Mon, 06 Jul 2026 11:00:06 EDT news702552216 Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that can be used to treat malignant tumors, using a genetic engineering technique called Platinum TALEN. https://medicalxpress.com/news/2026-07-platinum-talen-enables-mass-production.html Mon, 06 Jul 2026 09:00:08 EDT news702537900 A new study led by researchers at the University of Hawaiʻi Cancer Center found that at least $230 million was spent on cancer care delivered outside Hawaiʻi between 2021 and 2023, highlighting the significant financial impact of geographic isolation on patients and the health care system. https://medicalxpress.com/news/2026-07-patients-hawaii-spent-230m-state.html Fri, 03 Jul 2026 10:00:05 EDT news702286186 Researchers at Cima and Clinica Universidad de Navarra have identified new molecular mechanisms underlying multiple myeloma. This type of hematologic cancer, which affects the bone marrow, is characterized by its resistance to treatment, leading to relapses in patients. The researchers' paper is published in the journal Blood. https://medicalxpress.com/news/2026-07-identification-molecular-markers-multiple-myeloma.html Wed, 01 Jul 2026 17:00:02 EDT news702137521 Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma, a blood cancer that begins in plasma cells in the bone marrow. https://medicalxpress.com/news/2026-06-wearable-devices-cytokine-syndrome-earlier.html Mon, 22 Jun 2026 15:40:04 EDT news701360881 A new study led by researchers at The University of Texas MD Anderson Cancer Center has uncovered a previously unknown connection between nucleic acid structures called R-loops and age-related inflammation—or inflammaging—that could herald new intervention options for chronic inflammation and the subsequent health conditions. https://medicalxpress.com/news/2026-06-age-inflammation-treatment-pathway.html Wed, 17 Jun 2026 09:40:05 EDT news700903202 Patients with multiple myeloma who received a new immunotherapy combination lived significantly longer without their cancer worsening and showed early signs of improved survival in a large international clinical trial. https://medicalxpress.com/news/2026-06-combo-treatment-delays-multiple-myeloma.html Mon, 15 Jun 2026 17:50:03 EDT news700760821 A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers. The research found that GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide (brand names: Ozempic, Wegovy) and tirzepatide (brand names: Mounjaro and Zepbound), were associated with a 41% decrease in the overall risk of developing cancer among non-diabetic patients who used the drugs for weight management, compared to those who relied on diet and exercise alone. https://medicalxpress.com/news/2026-06-weight-loss-treatments-linked-obesity.html Sun, 07 Jun 2026 19:10:01 EDT news699810902 Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international Phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. https://medicalxpress.com/news/2026-05-teclistamab-remission-relapsed-myeloma-free.html Fri, 29 May 2026 17:00:01 EDT news699268747 An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation. https://medicalxpress.com/news/2026-05-ai-tool-personalize-multiple-myeloma.html Fri, 22 May 2026 11:40:02 EDT news698666103 Immunotherapy for cancer works like a guided missile, directing the body's immune cells toward tumor cells. However, not all immune cells respond to the call to attack, and this can lead to variability in treatment responses. As immune cell response is a critical factor in the likelihood of overcoming the disease, understanding why is paramount. https://medicalxpress.com/news/2026-05-elite-immune-cells-multiple-myeloma.html Thu, 21 May 2026 20:20:01 EDT news698572645 Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma. In two studies published this month in Blood Journal, they found that using the drug mezigdomide (a cereblon E3 ligase modulator developed by Bristol Myers Squibb) can help these cells regain their strength and better destroy cancer by restoring the immune system's ability to attack cancer and significantly improving the effectiveness of next-generation immunotherapies. https://medicalxpress.com/news/2026-05-reversing-cell-exhaustion-effectiveness-myeloma.html Mon, 18 May 2026 12:40:03 EDT news698322722 The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today announced that the Food and Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for a novel chimeric antigen receptor (CAR) T cell therapy. https://medicalxpress.com/news/2026-05-car-cell-therapy-clinical.html Fri, 15 May 2026 13:40:04 EDT news698069882 New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that people who gain the highest amount of weight across adulthood are at greatly increased risk of certain obesity-related cancers. The study is by Associate Professor Anton Nilsson and Associate Professor Tanja Stocks, Department of Translational Medicine, Lund University, Malmö, Sweden, and colleagues. The study is published on the preprint server medRxiv. https://medicalxpress.com/news/2026-05-people-gain-weight-cancers.html Thu, 14 May 2026 11:47:14 EDT news697977961